Source: Zacks

Alkermes: Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680

ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.

Read full article »
Alkermes's Competitors | Alkermes's News | Alkermes's Financials
Stay up-to-date with the latest news on Alkermes
Annual Revenue
$1.0-5.0B
Employees
1.0-5.0K
Richard Pops's photo - Chairman & CEO of Alkermes

Chairman & CEO

Richard Pops

CEO Approval Rating

61/100

Read more
Stay up-to-date with the latest news on Alkermes